- Waters Corporation (WAT, Financial) launches BioResolve Protein A Affinity Columns, marking the company's first foray into affinity chromatography.
- New columns offer up to 7x improvement in sensitivity and enable antibody titer measurements up to 2 days earlier.
- Product designed to simplify workflows and provide precise quantitation at lower concentrations.
Waters Corporation (WAT) has unveiled its BioResolve Protein A Affinity Columns featuring MaxPeak Premier Technology, a significant development as it marks their initial venture into the affinity chromatography market. The product promises to address critical bottlenecks in biotherapeutic development with its advanced capabilities.
The innovative BioResolve columns deliver up to a 7x boost in sensitivity when compared to current market leaders, primarily utilizing novel non-porous 3.5 ?m particles. This enhancement allows for more accurate quantitation at lower concentrations while using reduced sample volumes. Additionally, the new columns enable antibody titer measurements up to 2 days earlier than existing methods and offer 2x more attribute information through simplified workflows.
Available in 2.1 x 20 mm and 3.9 x 5 mm formats, these columns are designed to couple with size exclusion chromatography columns, facilitating both titer concentration and aggregate analysis in a single run on any liquid chromatography (LC) system. This feature significantly increases workflow efficiency and can potentially reduce project turnaround times, thereby fast-tracking the time to market for biologics.
Dr. Udit Batra, President and CEO of Waters Corporation, highlighted the columns' potential to expedite the development of lifesaving therapies by addressing one of the main bottlenecks in biotherapeutics—identifying and optimizing suitable cell lines for antibody production. The columns' integration into LC/MS setups without needing prior purification streamlines workflows even further.
This launch reinforces Waters Corporation's strategic position in the high-value biotherapeutics market, enhancing their analytical toolbox for biomolecule characterization. By offering improved efficiency and accuracy in bioprocessing, Waters aims to capture additional market share and reinforce their competitive stance in the growing biologics sector.
